CAS No.599-79-1,Salicylazosulfapyridine Suppliers,MSDS download

Products Categories

Pharmaceutical (161)
Organic Chemicals (38)
Others (30)
Reagent (7)
Adhesive and Sealant (3)
Plant Extract (2)
Materials (2)
(1)

Basic Information

Molecular Structure:
CAS No.:	599-79-1
Name:	Salicylazosulfapyridine
Article Data:	14

Formula:	C₁₈H₁₄N₄O₅S
Molecular Weight:	398.399
Synonyms:	Benzoicacid, 2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]- (9CI);Salicylicacid, 5-[[p-(2-pyridylsulfamoyl)phenyl]azo]- (6CI,7CI,8CI);5-[4-(2-Pyridylsulfamyl)phenylazo]-2-hydroxybenzoic acid;5-[p-(2-Pyridylsulfamyl)phenylazo]salicylicacid;Azopyrin;Azopyrine;Azulfidine;Azulfidine EN;Benzosulfa;Colo-Pleon;NSC 203730;NSC 667219;Reupirin;Salazopyridin;Salazopyrin;Salisulf;Sulfasalazin;
EINECS:	209-974-3
Density:	1.488 g/cm³
Melting Point:	260-265 °C (dec.)(lit.)
Boiling Point:	689.347 °C at 760 mmHg
Flash Point:	370.704 °C
Solubility:	NH₄OH 1 M: 50 mg/mL, clear, red
Appearance:	brownish-yellow crystals
Hazard Symbols:	Xn
Risk Codes:	42/43
Safety:	22-29/56-45
PSA:	149.69000
LogP:	4.85540

Synthetic route

: 144-83-2
sulphapyridine

: 69-72-7
salicylic acid

: 599-79-1
sulfosalazine

Conditions

Conditions	Yield
Stage #1: sulphapyridine With hydrogenchloride; sodium nitrite In water at 2℃; for 0.333333h; Stage #2: salicylic acid With sodium hydroxide In water at 7℃; for 1.5h; Temperature; Concentration;	95.4%
Stage #1: sulphapyridine With hydrogenchloride; sodium nitrite In water at 2℃; for 0.333333h; Stage #2: salicylic acid With sodium hydroxide In water at 7℃; for 1.5h; pH=10; Temperature; Time; Concentration;
Stage #1: sulphapyridine With hydrogenchloride; sodium nitrite In water at 0℃; Flow reactor; Stage #2: salicylic acid With glycine; sodium hydroxide In water; N,N-dimethyl-formamide at 25℃; pH=8.55 - 9; Flow reactor;

: 4-(Pyridin-2-ylsulfamoyl)-benzenediazonium; chloride

: 69-72-7
salicylic acid

: 599-79-1
sulfosalazine

Conditions

Conditions	Yield
With sodium hydroxide at 7℃; for 1.5h; pH=10; pH-value; Temperature;	94.9%

: 54-21-7
sodium salicylate

: C11H9ClN4O2S

: 599-79-1
sulfosalazine

Conditions

Conditions	Yield
Stage #1: sodium salicylate; C11H9ClN4O2S In water at -30℃; for 0.0138889h; Stage #2: With hydrogenchloride In water Temperature;	94.2%

: 89-57-6
5-Aminosalicylic Acid

: 1202816-93-0
4-nitrososulfopyridine

: 599-79-1
sulfosalazine

Conditions

Conditions	Yield
With hydrogenchloride In methanol; water at 20 - 50℃; pH=3; Concentration; pH-value; Temperature;	92.5%
With hydrogenchloride In methanol; water at 30 - 50℃; Temperature;	92.5%

: 504-29-0
2-aminopyridine

: 599-79-1
sulfosalazine

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1.1: potassium carbonate / 1.5 h / 5 °C 2.1: sodium hydroxide / dimethyl sulfoxide; water / 3 h / 90 °C 3.1: sodium nitrite; hydrogenchloride / water / 0.33 h / 2 °C 3.2: 1.5 h / 7 °C / pH 10 View Scheme

: 121-60-8
p-acetylaminobenzenesulfonyl chloride

: 599-79-1
sulfosalazine

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1.1: potassium carbonate / 1.5 h / 5 °C 2.1: sodium hydroxide / dimethyl sulfoxide; water / 3 h / 90 °C 3.1: sodium nitrite; hydrogenchloride / water / 0.33 h / 2 °C 3.2: 1.5 h / 7 °C / pH 10 View Scheme

: 64-17-5
ethanol

: 599-79-1
sulfosalazine

: ethyl 2-hydroxy-5-[(E)-2-{4-[(pyridine-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoate

Conditions

Conditions	Yield
With sulfuric acid for 8.5h; Reflux; Inert atmosphere;	87%

: zinc(II) hydroxide

: 599-79-1
sulfosalazine

: [Zn(sulfasalazine(-1H))(μ-OH)]

Conditions

Conditions	Yield
In ethanol; water High Pressure; under hydrothermal conditions; mixt. of ligand, Zn(OH)2, EtOH and H2O placed in Parr stainless steel vessel; sealed; heated to 110°C for 5 d; crystals isolated; elem. anal.;	40%

: zinc acetate hydrate

: 599-79-1
sulfosalazine

: [Zn(sulfasalazine(-1H))(μ-OH)]

Conditions

Conditions	Yield
In ethanol; water High Pressure; under hydrothermal conditions; mixt. of ligand, Zn acetate, EtOH and H2Oplaced in Parr stainless steel vessel; sealed; heated to 110°C f or 5 d; crystals isolated; elem. anal.;	40%

: C20H33N9O5

: 599-79-1
sulfosalazine

: C38H45N13O9S

Conditions

Conditions	Yield
With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dimethyl sulfoxide at 20℃; for 4h;	36%

Raw Materials

69-72-7

144-83-2

Downstream Products

89-57-6

144-83-2

Total:173 Page 1 of 5 1 2 3 4 5 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 599-79-1

Chemistry

Molecular Structure:

Molecular Formula: C₁₈H₁₄N₄O₅S
Molecular Weight: 398.3926
IUPAC Name: (3Z)-6-Oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid
Synonyms of Sulfasalazine (CAS NO.599-79-1): 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid ; 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene ; 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid ; 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid ; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid ; 5-22-08-00433 (Beilstein Handbook Reference) ; Accucol ; Asulfidine ; Azopyrin ; Azopyrine ; Azosulfidin ; Azulfidine ; Azulfidine EN-Tabs ; BRN 0356241 ; Benzoic acid, 2-hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)- ; Benzosulfa ; CCRIS 4713 ; Colo-Pleon ; EINECS 209-974-3 ; HSDB 3395 ; NSC 203730 ; NSC 667219 ; Reupirin ; Rorasul ; S.A.S. 500 ; S.A.S.-500 ; SASP ; SI-88 ; Salazo-sulfapyridinum ; Salazosulfapyridin ; Salazosulfapyridine ; Salazosulfapyridinum ; UNII-3XC8GUZ6CB ; W-T Sasp Oral
CAS NO: 599-79-1
Classification Code: Analgesics ; Analgesics, Non-Narcotic ; Anti-Inflammatory Agents ; Anti-infective agents ; Anti-inflammatory agents, non-steroidal ; Antibacterial ; Antirheumatic agents ; Drug / Therapeutic Agent ; Gastrointestinal agents ; Human Data ; Mutation data ; Peripheral Nervous System Agents ; Reproductive Effect ; Sensory System Agents ; Tumor data
Melting point: 260-265 °C
Index of Refraction: 1.691
Molar Refractivity: 102.381 cm³
Molar Volume: 267.677 cm³
Surface Tension: 65.715 dyne/cm
Density: 1.488 g/cm³
Flash Point: 370.704 °C
Enthalpy of Vaporization: 106.117 kJ/mol
Boiling Point: 689.347 °C at 760 mmHg

Uses

Sulfasalazine (CAS NO.599-79-1) is used in the treatment of granulomatous colitis.It's intestinal sulfa drugs, and have a special affinity with connective tissue. It is currently a better ulcer drug for the treatment of chronic conjunctivitis.

Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
child	TDLo	oral	3800mg/kg/19D (3800mg/kg)	LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), DIFFUSE"	American Journal of Digestive Diseases. Vol. 23, Pg. 956, 1978.
human	TDLo	oral	429mg/kg/10D- (429mg/kg)	BLOOD: OTHER HEMOLYSIS WITH OR WITHOUT ANEMIA	New England Journal of Medicine. Vol. 289, Pg. 491, 1973.
man	LDLo	oral	3200mg/kg/31D (3200mg/kg)	BLOOD: AGRANULOCYTOSIS SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" BLOOD: OTHER CHANGES	Journal of the Royal Society of Medicine. Vol. 73, Pg. 587, 1980.
man	TDLo	oral	7143ug/kg (7.143mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING	New England Journal of Medicine. Vol. 306, Pg. 409, 1982.
man	TDLo	oral	143mg/kg/10D- (143mg/kg)	BLOOD: THROMBOCYTOPENIA	Annals of Internal Medicine. Vol. 102, Pg. 277, 1985.
man	TDLo	oral	357mg/kg (357mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: HEADACHE	Journal of Toxicology, Clinical Toxicology. Vol. 29, Pg. 543, 1991.
man	TDLo	oral	1286mg/kg/30D (1286mg/kg)	LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BLOOD: EOSINOPHILIA BLOOD: CHANGES IN CELL COUNT (UNSPECIFIED)	Internal Medicine. Vol. 31, Pg. 108, 1992.
man	TDLo	oral	122gm/kg/8Y-I (122000mg/kg)	PERIPHERAL NERVE AND SENSATION: PARESTHESIS VASCULAR: OTHER CHANGES	Postgraduate Medical Journal. Vol. 56, Pg. 106, 1980.
man	TDLo	rectal	7143ug/kg (7.143mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING	New England Journal of Medicine. Vol. 306, Pg. 409, 1982.
man	TDLo	unreported	1300mg/kg/4W- (1300mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" GASTROINTESTINAL: NAUSEA OR VOMITING BEHAVIORAL: ATAXIA	Practitioner. Vol. 204, Pg. 850, 1970.
mouse	LD50	intravenous	1096mg/kg (1096mg/kg)		Drugs in Japan Vol. -, Pg. 420, 1990.
mouse	LD50	oral	12500mg/kg (12500mg/kg)		Drugs in Japan Vol. -, Pg. 420, 1990.
mouse	LD50	subcutaneous	3gm/kg (3000mg/kg)		Drugs in Japan Vol. -, Pg. 420, 1990.
rabbit	LD50	oral	> 7500mg/kg (7500mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 953, 1995.
rat	LD50	intravenous	1520mg/kg (1520mg/kg)		Drugs in Japan Vol. -, Pg. 420, 1990.
rat	LD50	oral	15600mg/kg (15600mg/kg)		Drugs in Japan Vol. -, Pg. 420, 1990.
rat	LD50	subcutaneous	3870mg/kg (3870mg/kg)		Drugs in Japan Vol. -, Pg. 420, 1990.
women	LDLo	unreported	840mg/kg/3W-I (840mg/kg)	LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), DIFFUSE" SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" IMMUNOLOGICAL INCLUDING ALLERGIC: INCREASED IMMUNE RESPONSE	Therapie. Vol. 37, Pg. 315, 1982.
women	TDLo	oral	140mg/kg/2W-I (140mg/kg)	BEHAVIORAL: HEADACHE GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Lancet. Vol. 1, Pg. 917, 1984.
women	TDLo	oral	570mg/kg/11D- (570mg/kg)	BLOOD: LEUKOPENIA BLOOD: THROMBOCYTOPENIA BLOOD: OTHER CHANGES	Clinical and Experimental Dermatology. Vol. 19, Pg. 419, 1994.
women	TDLo	oral	700mg/kg/4W-I (700mg/kg)	BEHAVIORAL: EXCITEMENT LIVER: LIVER FUNCTION TESTS IMPAIRED BLOOD: CHANGES IN LEUCOCYTE (WBC) COUNT	Clinical and Experimental Rheumatology. Vol. 10, Pg. 427, 1992.
women	TDLo	unreported	2700mg/kg/13W (2700mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	British Medical Journal. Vol. 286, Pg. 1547, 1983.

Safety Profile

Hazard Codes of Sulfasalazine (CAS NO.599-79-1): Harmful Xn
Risk Statements: 42/43
R42/43: May cause sensitization by inhalation and skin contact.
Safety Statements: 22-29/56-45
S22: Do not breathe dust.
S29: Do not empty into drains.
S56: Dispose of this material and its container at hazardous or special waste collection point.
S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
WGK Germany: 2
F: 8